Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Genitourinary 1Endocrine 1CNS 1

Conditions

Thyroid Cancer, Papillary 2Sarcoma 2Salivary Gland Neoplasms 2Brain Neoplasms 2Wilms Tumor 1Solid Tumors 1Sarcoma, Ewing 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Nephroma, Mesoblastic 1Neoplasm Metastasis 1Melanoma 1Medulloblastoma 1Lymphoma, Large-Cell, Anaplastic 1Locally Advanced Solid Tumors 1Head and Neck Neoplasms 1Glioma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

sodium thiosulfate 1entrectinib 1Restraint, Physical 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Medulloblastoma × entrectinib × Clear all
NCT02650401 2026-03-25

STARTRK-NG

Hoffmann-La Roche

Phase 1/2 Active not recruiting
69 enrolled 1 FDA
CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡